The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease?
Abstract
Multiple sclerosis is (MS) a T‐cell autoimmune disease characterized by a relapsing‐remitting followed by a progressive phase. Relapses are driven by the adaptive immune system and involve waves of T helper cell 1 (Th1), Th17, and CD8 cells that infiltrate the nervous system and provoke a attack. These cells are modulated by regulatory T and B cells. Infiltration of T cells into the nervous system initiates a complex immunological cascade consisting of epitope spreading, which triggers new attacks, and activation of the innate immune system (microglia, dendritic cells, astrocytes, B cells), which leads to chronic inflammation. The secondary progressive phase is due to neurodegeneration triggered by inflammation and is driven by the innate immune system. Why a shift to the progressive stage occurs and how to prevent it is a central question in MS. Effective treatment of MS must affect multiple disease pathways: suppression of proinflammatory T cells, induction of regulatory T cells, altering traffic of cells into the nervous system, protecting axons and myelin, and controlling innate immune responses. Without biomarkers, the clinical and pathological heterogeneity of MS makes treatment difficult. Treatment is further hampered by untoward adverse effects caused by immune suppression. Nonetheless, major progress has been made in the understanding and treatment of MS. There are three definitions of cure as it applies to MS: (1) halt progression of disease, (2) reverse neurological deficits, and (3) prevent MS. Although the pathways to each of these cures are linked, each requires a unique strategy. Ann Neurol 2009;65:239–248
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Multiple Sclerosis and Epstein-Barr Virus
Levin, L. I., Munger, K. L., Rubertone, M. V., Peck, C. A., Lennette, E. T., Spiegelman, D., & Ascherio, A. (2003) · JAMA · doi:10.1001/jama.289.12.1533 · Cited by 165
RetractedBettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992
Self-citationRegulatory T Cells and Immune Tolerance
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,325
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor
Quintana, F. J., Basso, A. S., Iglesias, A. H., Korn, T., Farez, M. F., Bettelli, E., Caccamo, M., Oukka, M., & Weiner, H. L. (2008) · Nature · doi:10.1038/nature06880 · Cited by 1,865
Self-citationLoss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis
Viglietta, V., Baecher-Allan, C., Weiner, H. L., & Hafler, D. A. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031579 · Cited by 1,856
Self-citationCortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Kebir, H., Kreymborg, K., Ifergan, I., Dodelet-Devillers, A., Cayrol, R., Bernard, M., Giuliani, F., Arbour, N., Becher, B., & Prat, A. (2007) · Nature Medicine · doi:10.1038/nm1651 · Cited by 1,759 · cited 1×
“It is now recognized that Th17 cells play a crucial role in autoimmunity in the EAE model,(12) and increased numbers of Th17 cells have been identified in MS as well.(13) Both types of pathogenic cells (Th1 and Th17) most probably play a role in MS and could account for the immunological and clinical heterogeneity of…”
BackgroundRisk Alleles for Multiple Sclerosis Identified by a Genomewide Study
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa073493 · Cited by 1,746 · cited 1×
“Recent studies have begun to identify genes that are associated with MS, and they are related to the immune system.(6) The major genetic factor in MS is the major histocompatibility complex, which overshadows other susceptibility genes that have been identified (eg, interleukin-7 [IL-7], IL-2).”
BackgroundMagliozzi, R., Howell, O., Vora, A., Serafini, B., Nicholas, R., Puopolo, M., Reynolds, R., & Aloisi, F. (2006) · Brain · doi:10.1093/brain/awm038 · Cited by 1,443
Cited by
The immunology of stroke: from mechanisms to translation
Iadecola, C., & Anrather, J. (2011) · Nature Medicine · doi:10.1038/nm.2399 · Cited by 2,596
“In multiple sclerosis, the classical inflammatory disease of the central nervous system (CNS), elements of innate and adaptive immunity are engaged in the post-ischemic brai”
BackgroundAn automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis
Schmidt, P., Gaser, C., Arsic, M., Buck, D., Förschler, A., Berthele, A., Hoshi, M., Ilg, R., Schmid, V. J., Zimmer, C., et al. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2011.11.032 · Cited by 1,223
Evidence for a two-stage disability progression in multiple sclerosis
Leray, E., Yaouanq, J., Le Page, E., Coustans, M., Laplaud, D., Oger, J., & Edan, G. (2010) · Brain · doi:10.1093/brain/awq076 · Cited by 596
Cannabinoids as Novel Anti-Inflammatory Drugs
Nagarkatti, P., Pandey, R., Rieder, S. A., Hegde, V. L., & Nagarkatti, M. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.93 · Cited by 555
“Multiple sclerosis (MS) is an autoimmune disorder that is mediated by myelin-specific selfreactive T cells, macrophages/microglial cells and astrocytes [3,42].”
Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation
Mayo, L., Trauger, S. A., Blain, M., Nadeau, M., Patel, B., Alvarez, J. I., Mascanfroni, I. D., Yeste, A., Kivisäkk, P., Kallas, K., et al. (2014) · Nature Medicine · doi:10.1038/nm.3681 · Cited by 472
Self-citationCNS inflammation and neurodegeneration
Chitnis, T., & Weiner, H. L. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90609 · Cited by 470
Self-citationBrain health: time matters in multiple sclerosis
Giovannoni, G., Butzkueven, H., Dhib-Jalbut, S., Hobart, J., Kobelt, G., Pepper, G., Sormani, M. P., Thalheim, C., Traboulsee, A., & Vollmer, T. (2016) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2016.07.003 · Cited by 458
Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis
Dutta, R., & Trapp, B. D. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.09.005 · Cited by 457
Multifaceted interactions between adaptive immunity and the central nervous system
Kipnis, J. (2016) · Science · doi:10.1126/science.aag2638 · Cited by 376
Starossom, S. C., Mascanfroni, I. D., Imitola, J., Cao, L., Raddassi, K., Hernandez, S. F., Bassil, R., Croci, D. O., Cerliani, J. P., Delacour, D., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.05.023 · Cited by 354
Role of the innate immune system in the pathogenesis of multiple sclerosis
Gandhi, R., Laroni, A., & Weiner, H. L. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.10.015 · Cited by 331
Self-citationThe molecular basis of neurodegeneration in multiple sclerosis
Lassmann, H., & van Horssen, J. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.08.004 · Cited by 294
Müller, M., Carter, S., Hofer, M. J., & Campbell, I. L. (2010) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01089.x · Cited by 293
Lim, C. K., Bilgin, A., Lovejoy, D. B., Tan, V., Bustamante, S., Taylor, B. V., Bessede, A., Brew, B. J., & Guillemin, G. J. (2017) · Scientific Reports · doi:10.1038/srep41473 · Cited by 255
CXCR4 promotes differentiation of oligodendrocyte progenitors and remyelination
Patel, J. R., McCandless, E. E., Dorsey, D., & Klein, R. S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006301107 · Cited by 231
Patel, J. R., Williams, J. L., Muccigrosso, M. M., Liu, L., Sun, T., Rubin, J. B., & Klein, R. S. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1034-0 · Cited by 134
Haves-Zburof, D., Paperna, T., Gour-Lavie, A., Mandel, I., Glass-Marmor, L., & Miller, A. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01229.x · Cited by 72
Omura, S., Sato, F., Martinez, N. E., Park, A.-M., Fujita, M., Kennett, N. J., Cvek, U., Minagar, A., Alexander, J. S., & Tsunoda, I. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00516 · Cited by 20
“There have been controversies on whether MS is a heterogeneous or homogenous disease (12, 47, 62).”
Background
Metadata
- Authors
- Weiner, H. L.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2009-03
- Volume
- 65
- Issue
- 3
- Pages
- 239-248
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1992692157
- Cited by
- 344
- References
- 91
- FWCI
- 28.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.